Literature DB >> 26188107

Prenatal ethanol exposure-induced adrenal developmental abnormality of male offspring rats and its possible intrauterine programming mechanisms.

Hegui Huang1, Zheng He1, Chunyan Zhu1, Lian Liu1, Hao Kou1, Lang Shen1, Hui Wang2.   

Abstract

Fetal adrenal developmental status is the major determinant of fetal tissue maturation and offspring growth. We have previously proposed that prenatal ethanol exposure (PEE) suppresses fetal adrenal corticosterone (CORT) synthesis. Here, we focused on PEE-induced adrenal developmental abnormalities of male offspring rats before and after birth, and aimed to explore its intrauterine programming mechanisms. A rat model of intrauterine growth retardation (IUGR) was established by PEE (4g/kg·d). In PEE fetus, increased serum CORT concentration and decreased insulin-like growth factor 1 (IGF1) concentration, with lower bodyweight and structural abnormalities as well as a decreased Ki67 expression (proliferative marker), were observed in the male fetal adrenal cortex. Adrenal glucocorticoid (GC)-metabolic activation system was enhanced while gene expression of IGF1 signaling pathway with steroidogenic acute regulatory protein (StAR), 3β-hydroxysteroid dehydrogenase (3β-HSD) was decreased. Furthermore, in the male adult offspring of PEE, serum CORT level was decreased but IGF1 was increased with partial catch-up growth, and Ki67 expression demonstrated no obvious change. Adrenal GC-metabolic activation system was inhibited, while IGF1 signaling pathway and 3β-HSD was enhanced with the steroidogenic factor 1 (SF1), and StAR was down-regulated in the adult adrenal. Based on these findings, we propose a "two-programming" mechanism for PEE-induced adrenal developmental toxicity: "the first programming" is a lower functional programming of adrenal steroidogenesis, and "the second programming" is GC-metabolic activation system-related GC-IGF1 axis programming.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adrenal steroidogenesis; Glucocorticoid-metabolic system; Glucocorticoid–insulin-like growth factor 1 axis; Intrauterine growth retardation; Intrauterine programming; Prenatal ethanol exposure

Mesh:

Substances:

Year:  2015        PMID: 26188107     DOI: 10.1016/j.taap.2015.07.005

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  5 in total

1.  Low H3K27 acetylation of SF1 in PBMC: a biomarker for prenatal dexamethasone exposure-caused adrenal insufficiency of steroid synthesis in male offspring.

Authors:  Guanghui Chen; Can Ai; Fangfang Duan; Yawen Chen; Jiangang Cao; Jinzhi Zhang; Ying Ao; Hui Wang
Journal:  Cell Biol Toxicol       Date:  2022-03-04       Impact factor: 6.691

2.  Prenatal dexamethasone exposure programs the decreased testosterone synthesis in offspring rats by low level of endogenous glucocorticoids.

Authors:  Min Liu; Yi Liu; Lin-Guo Pei; Qi Zhang; Hao Xiao; Ya-Wen Chen; Hui Wang
Journal:  Acta Pharmacol Sin       Date:  2021-10-25       Impact factor: 7.169

3.  Steroidogenic factor-1 hypermethylation in maternal rat blood could serve as a biomarker for intrauterine growth retardation.

Authors:  Dong-Mei Wu; Liang-Peng Ma; Gui-Li Song; Yong Long; Han-Xiao Liu; Yang Liu; Jie Ping
Journal:  Oncotarget       Date:  2017-10-10

4.  Programming for increased expression of hippocampal GAD67 mediated the hypersensitivity of the hypothalamic-pituitary-adrenal axis in male offspring rats with prenatal ethanol exposure.

Authors:  Juan Lu; Zhexiao Jiao; Ying Yu; Chong Zhang; Xia He; Qiang Li; Dan Xu; Hui Wang
Journal:  Cell Death Dis       Date:  2018-05-31       Impact factor: 8.469

5.  Glucocorticoid mediates prenatal caffeine exposure-induced endochondral ossification retardation and its molecular mechanism in female fetal rats.

Authors:  Yangfan Shangguan; Hongqiang Jiang; Zhengqi Pan; Hao Xiao; Yang Tan; Kai Tie; Jun Qin; Yu Deng; Liaobin Chen; Hui Wang
Journal:  Cell Death Dis       Date:  2017-10-26       Impact factor: 8.469

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.